| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10018193 | HBV | ENSG00000082556.14 | protein_coding | OPRK1 | No | No | 4986 | P41145 |
| TVIS20013017 | HPV | ENSG00000082556.14 | protein_coding | OPRK1 | No | No | 4986 | P41145 |
| TVIS20021008 | HPV | ENSG00000082556.14 | protein_coding | OPRK1 | No | No | 4986 | P41145 |
| TVIS20013016 | HPV | ENSG00000082556.14 | protein_coding | OPRK1 | No | No | 4986 | P41145 |
| TVIS20062745 | HPV | ENSG00000082556.14 | protein_coding | OPRK1 | No | No | 4986 | P41145 |
| TVIS44020000 | HTLV-1 | ENSG00000082556.14 | protein_coding | OPRK1 | No | No | 4986 | P41145 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | OPRK1 |
|---|---|
| DrugBank ID | DB00611 |
| Drug Name | Butorphanol |
| Target ID | BE0000632 |
| UniProt ID | P41145 |
| Regulation Type | agonist |
| PubMed IDs | 10381785; 10779697; 12127012; 12470863; 15942128; 8968334; 8746803; 7705457; 2555580; 17909753 |
| Citations | Vivian JA, DeYoung MB, Sumpter TL, Traynor JR, Lewis JW, Woods JH: kappa-Opioid receptor effects of butorphanol in rhesus monkeys. J Pharmacol Exp Ther. 1999 Jul;290(1):259-65.@@Park Y, Jang CG, Ho IK, Ko KH: kappa-opioid agonist stimulated regional distribution of [(35)S]GTPgammas binding in butorphanol continuously infused rat. Brain Res Bull. 2000 May 1;52(1):17-20.@@Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60.@@Fan LW, Tanaka S, Park Y, Sasaki K, Ma T, Tien LT, Rockhold RW, Ho IK: Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding. Brain Res. 2002 Dec 27;958(2):277-90.@@Commiskey S, Fan LW, Ho IK, Rockhold RW: Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. Epub 2005 Jun 8.@@Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41.@@Wakabayashi H, Tokuyama S, Ho IK: Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine. Neurochem Res. 1995 Oct;20(10):1179-85.@@Narita M, Feng Y, Makimura M, Hoskins B, Ho IK: Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain. Eur J Pharmacol. 1994 Dec 27;271(2-3):547-50.@@Ohta S, Niwa M, Nozaki M, Tsurumi K, Shimonaka H, Tanahashi T, Uematsu H, Yamamoto M, Fujimura H: [Kappa-type opioid receptor in human placental membrane]. Masui. 1989 Oct;38(10):1293-300.@@Walsh SL, Chausmer AE, Strain EC, Bigelow GE: Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl). 2008 Jan;196(1):143-55. Epub 2007 Oct 2. |
| Groups | Approved; Illicit; Vet_approved |
| Direct Classification | Phenanthrenes and derivatives |
| SMILES | [H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1 |
| Pathways | |
| PharmGKB | PA164745398 |
| ChEMBL | CHEMBL33986 |
